Navigation Links
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:3/12/2009

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME).

This 36-month, open-label, Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide (FA), after administration of Iluvien in patients with DME. Secondarily, the PK Study is designed to provide information on the safety and efficacy of Iluvien in a DME patient population. A total of 37 subjects were enrolled in the PK Study, 20 patients on the low dose of Iluvien (an approximate 0.23 micrograms per day dose), and 17 patients on the high dose of Iluvien (an approximate 0.45 micrograms per day dose).

In the 12-month interim readout, no adverse events related to intraocular pressure (IOP) were seen in low dose patients, and 23.5 percent of the high dose patients experienced IOP increases of 30 millimeters of mercury (mmHg) or greater at some time point. By way of comparison, in published results from clinical studies of DME patients using sustained release intravitreal FA in Bausch & Lomb Incorporated's product Retisert(R), a surgically implanted intravitreal drug delivery device containing 0.59 mg FA approved for the treatment of chronic non-infectious posterior uveitis, 35 percent of the patients experienced IOP increases of 30 mmHg or greater at some time point during the first year.

"This profile of IOP changes occurring only in the high dose group is consistent with the IOP change profiles that
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... UBS Global Healthcare Conference in New York ... at 11 a.m. Eastern Time. To listen to the ... the Investor Relations section of the Company,s Web site at ... days after the event. About Orexigen® Therapeutics ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... PLYMOUTH MEETING, Pa., June 9 Genaera,Corporation ... presentation by Genaera,scientists of preclinical data on ... treatment of type 2 diabetes and obesity, ... Diabetes Association in San,Francisco, California., The ...
... SUNNYVALE, Calif., June 9 Pharmacyclics, Inc.,(Nasdaq: ... study evaluating,PCI-32765, an orally available, selective inhibitor of ... an established animal model,for rheumatoid arthritis (RA). The ... Societies (FOCIS) meeting being held this,week in Boston, ...
Cached Medicine Technology:Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 2Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 3Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 4Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Drugs,(NYSE: LDG ) announced its flu immunization program at ... of those communities remain,healthy and combat the annual flu season. ... meet its customers, needs. -- Longs Drugs will be ... beginning in October through the middle of November. ...
... for Trading on OTC Bulletin Board Shortly -, ... Board: EMED) announced today that the U.S. Securities and,Exchange ... by Card Activation Technologies, Inc. As a result of,the ... its Form 211 application, as filed with the NASD, ...
... 24 With the cold and,flu season now upon ... to washing their hands on a regular basis because,according ... hands is,the single most important measure people can take ... "Studies have shown that 40 percent of women and ...
... Cancer Center at Jefferson and Thomas Jefferson University Hospital ... implant radiation-emitting seeds in prostate cancer patients. While the ... based in The Netherlands, is only being used for ... help with the actual placement of the seeds. To ...
... Hope",charity auction, hosted by Pittsburgh Steeler Alan Faneca and his ... - 11 p.m. at the Jerome,Bettis Grille 36 on the ... the evening off with an autograph session from 7-8,p.m. Throughout ... of sports,memorabilia will take place. Local sportscaster Bob Pompeani will ...
... PRINCETON, N.J., Sept. 23 Covance Inc. (NYSE:,CVD) today ... Life Sciences,Conference on September 24 at 3:30 pm ET. ... http://www.covance.com . In order to register and,download any ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine News:Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:MedCom USA's Subsidiary Card Activation Technologies, Inc.'s SB2 Registration Declared Effective by SEC 2Health News:Clean Hands are Key to Fighting Cold, Flu Germs 2Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Super Bowl Champion, Pro Bowler and Pittsburgh Steeler Alan Faneca to Host Sixth Annual 'Bid for Hope' Auction 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: